slides · global inventory
Consultants Gambit
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 39,432
Current window 34,141-34,170
Pages 1,315
Rows per page 30
Arc
34,141-34,170 of 39,432
23
The table uses a red dashed box to highlight the core clinical data rows.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
24
The slide highlights specific safety data points for a competitor product to establish a benchmark.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
25
The slide uses a structured table format to map clinical trial progress against specific disease indications.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
26
The diagram illustrates a dose escalation study design with three cohorts leading to the RP2D.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
27
The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
28
Includes scientific diagrams of molecular pathways and comparative efficacy charts.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
29
The slide uses three bar charts to compare IMX-110 performance against benchmarks in mouse models.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
30
Includes a process diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
31
Includes survival curves (Kaplan-Meier), tumor imaging, and tumor frequency metrics.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
32
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
33
Includes two side-by-side clinical data visualizations (line charts and bar charts) comparing patient outcomes.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
34
The slide uses a bubble chart to map clinical trial outcomes against patient treatment history and a table to detail specific drug performance metrics.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
35
The chart is a conceptual visualization of 100% of patients achieving 4 months mPFS.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
36
Shows two parallel clinical tracks: monotherapy and combination with tislelizumab.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
37
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
38
The slide uses a process-oriented layout to connect platform capabilities to specific product outputs.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
39
The slide uses a process-like flow from the 3 pillars to the specific product applications.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
40
Includes technical diagrams of the drug construct, comparative histology, and survival curves.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
41
Includes two sets of charts: tumor volume line graphs and survival curves. References Abouzeid et al. (2013/2014).Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
42
Includes detailed scientific diagrams and references to clinical studies.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
43
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
44
The slide uses a grid-like layout to present headshots, names, titles, and institutional logos for advisory board members.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
45
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
46
The slide is divided into two rows: top row for ImmixBio board members, bottom row for Nexcella board members.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
47
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
48
The slide uses a bar chart to contrast two groups of drugs by their combined annual sales, effectively framing the market size for potential TSTx applications.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
49
The slide compares efficacy of Humira, Stelara, and Entyvio against placebo in clinical trials.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
01
UBS | Results Presentation Deck | 41 slidesUBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Situation & Context1 hit
02
UBS | Results Presentation Deck | 41 slidesUBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Situation & Context1 hit
03
UBS | Results Presentation Deck | 41 slidesUBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Situation & Context1 hit